Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants.

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Researchers have discovered how pancreatic cancer reprograms its surroundings to spread quickly and stealthily. By using a protein called periostin, the tumor remodels nearby tissue and invades nerves ...

Pancreatic cancer has long been one of medicine’s most unforgiving puzzles, killing most patients within a few years and often within months. Now a cluster of advances is giving researchers something ...

A multidisciplinary team of University of Cincinnati Cancer Center researchers has received a $40,000 Ride Cincinnati grant to study a delayed release preparation, or wafer, of an immunostimulatory ...